- India stocks rise for 3rd week as Fed rate cut, US trade talks lift sentiment Reuters
- Nifty gain 110 points, Sensex surge 400 pts in opening as investors cheer Fed’s 25 bps rate cut ANI News
- Mindtree, Infosys, Wipro lead IT rally on Fed rate easing | Tap to know more | Inshorts Inshorts
- Top 10@10: Gold eases post-Fed cut, Sitharaman’s call to invest, SEBI clears Adani, & more LinkedIn
- First Tick: Top global cues to watch in today’s trade TradingView
Blog
-
India stocks rise for 3rd week as Fed rate cut, US trade talks lift sentiment – Reuters
-
PSB Threatens Action Against Pakistan Baseball Federation
The already strained relationship between the Pakistan Sports Board (PSB) and national sports federations has taken another hit after the PSB served a show-cause notice to the Pakistan Federation Baseball (PFB) and threatened appropriate action over protocol violations.
In its official notice, the PSB is seeking an explanation from the Pakistan Federation Baseball over the team’s participation in an international event in Chinese Taipei without prior approval.
According to the notice, the national baseball team competed in the 12th BFA U15 Baseball Championship in August 2025 despite failing to secure the mandatory No Objection Certificate (NOC) from the PSB. The board described the move as a “direct breach of rules, reflecting gross negligence, disregard for official protocol, and failure to uphold responsibilities.”
The PSB further pointed out that the federation had previously been accused of forging documents to justify its participation in the 2024 Taipei event, an issue already under investigation by the Federal Investigation Agency (FIA). Officials said the repeated violations demonstrate a “pattern of misconduct and misrepresentation” that has raised serious concerns within the country’s sports governance structure.
The notice warned that non-compliance with directives could lead to the suspension of the federation’s operations and even legal proceedings. The baseball federation has been given seven days to provide a detailed explanation for its actions.
This latest development highlights the growing disconnect between the PSB and several national federations, with disputes over funding, oversight, and NOC approvals becoming increasingly frequent. For many federations, the PSB’s rigid control over international participation has been a point of contention, while the board insists that compliance is essential to maintaining transparency and accountability.
The Pakistan Federation Baseball has not yet issued a public response. However, with the threat of suspension looming, the episode could escalate into another flashpoint in the long-running tussle between the PSB and the country’s sports federations, with athletes once again left to bear the brunt of the issue.
Continue Reading
-
Indian Rupee recovers on US-India trade deal optimism
- The Indian Rupee claws back early losses against the US Dollar on US-India trade deal optimism.
- The US Initial Jobless Claims for the week ending September 13 came in lower at 231K.
- India’s CEA Nageswaran expresses optimism that US-India trade tensions will resolve in a couple of months.
The Indian Rupee (INR) recovers early losses and turns positive against the US Dollar (USD) during late trading hours in India on Friday. The USD/INR pair drops to near 88.20 on optimism over the United States (US)-India trade agreement. Investors turn optimistic on improving US-India trade relations after comments from India’s Chief Economic Adviser (CEA) V. Anantha Nageswaran on Thursday, in a gathering in Kolkata, stating that Washington might roll back the 25% tariff penalty on Indian imports in the next couple of months.
“Beneath the surface, lots of conversations are going on between the two governments. Although I don’t have a crystal ball or any insider information, I can say that my personal confidence is that in the next couple of months, if not earlier, we will see a resolution, at least to the extra tariff of 25%,” Nageswaran said, Mint reported.
Washington imposed an extra 25% tariff on India in early August for buying Oil from Russia, blaming India for indirectly funding Moscow for continuing the war with Ukraine.
India’s CEA Nageswaran has also expressed confidence that the US will reduce 25% reciprocal tariffs on New Delhi to between 10% and 15%.
India-made products would regain their glory in the global market if the US reduces tariffs on imports from New Delhi as projected. The ongoing trade tensions between the US and India have significantly impacted the interest of overseas investors in the Indian stock market.
Foreign Institutional Investors (FIIs) have pared stake worth Rs. 1,05,532 crores in Indian equity markets since the first day of July this year.
The table below shows the percentage change of Indian Rupee (INR) against listed major currencies today. Indian Rupee was the strongest against the British Pound.
USD EUR GBP JPY CAD AUD INR CHF USD 0.21% 0.35% 0.00% 0.12% 0.18% -0.11% 0.43% EUR -0.21% 0.16% -0.28% -0.09% -0.07% -0.31% 0.21% GBP -0.35% -0.16% -0.40% -0.25% -0.23% -0.50% 0.05% JPY 0.00% 0.28% 0.40% 0.11% 0.31% -0.14% 0.29% CAD -0.12% 0.09% 0.25% -0.11% 0.06% -0.22% 0.30% AUD -0.18% 0.07% 0.23% -0.31% -0.06% -0.29% 0.28% INR 0.11% 0.31% 0.50% 0.14% 0.22% 0.29% 0.38% CHF -0.43% -0.21% -0.05% -0.29% -0.30% -0.28% -0.38% The heat map shows percentage changes of major currencies against each other. The base currency is picked from the left column, while the quote currency is picked from the top row. For example, if you pick the Indian Rupee from the left column and move along the horizontal line to the US Dollar, the percentage change displayed in the box will represent INR (base)/USD (quote).
Daily digest market movers: Fed signals two more interest rate cuts this year
- The Indian Rupee gains against the US Dollar even as the latter gained ground after the monetary policy announcement by the Federal Reserve (Fed) on Wednesday, in which it reduced interest rates by 25 basis points (bps) to 4.00%-4.25%.
- During the press time, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, extends its upside to near 97.60
- However, the outlook of the US Dollar remains uncertain as the closely tracked Fed’s dot plot has signaled that the United States (US) central bank will cut interest rates two times more in the remainder of the year, along with one rate cut each in 2026 and 2027.
- Meanwhile, better-than-projected Initial Jobless Claims data for the week ending September 13 has also offered some support to the US Dollar. The Department of Labour reported on Thursday that the number of individuals seeking jobless benefits for the first time came in lower at 231K than estimates of 240K and the prior reading of 264K.
- Going forward, investors will focus on the speech from San Francisco Fed President Mary Daly scheduled at 18:30 GMT. Investors would look for cues regarding the pace of interest rate cuts by the Fed in the monetary policy meeting ahead.
Technical Analysis: USD/INR holds 20-day EMA
USD/INR retreats to near 88.20 on Friday. However, the near-term trend of the pair remains bullish as it stays above the 20-day Exponential Moving Average (EMA), which currently trades around 88.08.
The 14-day Relative Strength Index (RSI) struggles to recover above 60.00, suggesting that the bullish momentum has over for now.
Looking down, the 20-day EMA will act as key support for the major. On the upside, the September 11 high of 88.65 would be the key hurdle for the pair.
Continue Reading
-
Lahore ATC issues arrest warrants for 8 absconders in Jinnah House, Askari Tower cases
The Lahore Anti-Terrorism Court has issued arrest warrants for eight absconding suspects in connection with two May 9 cases.
Judge Manzar Ali Gill, while hearing the cases, proceeded against the absent accused.
In the Jinnah House attack case, arrest warrants were issued for Khadija Shah, Imran, and Faiza Azmat, while in the Askari Tower attack case, warrants were issued for Usman, Ahmed Mursaleen, Hamza Sohail, and Muhammad Khalid.
The court also began proceedings to declare two suspects Abdul Razzaq and Safdar as proclaimed offenders after they failed to appear despite earlier warrants. Public notices were ordered against them.
Continue Reading
-
Fostering the Fertile Ground for Compute, Empowering AI Pioneers for Industries
SHANGHAI, Sept. 19, 2025 /PRNewswire/ — On the second day of HUAWEI CONNECT 2025, Zhang Ping‘an, Huawei’s Executive Director of the Board and CEO of Huawei Cloud, delivered a keynote speech titled “All Intelligence: Empowering AI Pioneers for Industries”. He shared Huawei Cloud’s innovation and practices in AI compute services, foundation models, embodied AI, AI agents, and much more.
Constant innovation in AI Compute Service: Unleashing powerful compute in the intelligent era
Zhang Ping’an, Huawei’s Executive Director of the Board and CEO of Huawei Cloud
This year, Huawei Cloud announced its AI Compute Service powered by CloudMatrix384. The specifications of the Huawei CloudMatrix supernode will be upgraded from 384 cards to 8,192 cards. The supernodes can support a hyperscale cluster running on 500,000 to 1 million cards, thus providing robust AI compute, an invaluable resource in the intelligent era. Huawei Cloud also announced innovative memory storage with its Elastic Memory Service (EMS), which achieved an industry first by expanding video RAM with memory. This drastically reduces the latency of multi-round conversations on foundation models, greatly improving user experience.
Huawei Cloud has deployed fully liquid-cooled AI data centers in China’s Guizhou, Inner Mongolia, and Anhui. These AI data centers support 80 kW heat dissipation per cabinet, reduce power usage effectiveness (PUE) to 1.1, and offer AI-enabled O&M. This means enterprises do not need to reconstruct traditional data centers or build new ones. Instead, they require only a pair of optical fibers in order to connect to the data center and access efficient AI compute, as well as full-stack dedicated AI cloud services, on Huawei Cloud.
Zhang Ping‘an pointed out that Huawei Cloud’s AI Token Service abstracts away the underlying technical complexity and directly provides users with the final AI computing results. This allows users to utilize the inference computing power in the most efficient way possible. The CloudMatrix384 supernode realizes the full pooling of compute, memory, and storage resources, decouples compute tasks, storage tasks, and AI expert systems, and converts serial tasks into distributed parallel tasks, greatly improving the inference performance of the system. In scenarios involving inference tasks with different latency requirements, such as online, nearline, and offline inference, CloudMatrix384 delivers an average inference performance per card that is 3 to 4 times that of H20.
At the conference, Zhang Ping‘an announced the official launch of the AI Token Service powered by CloudMatrix384. The service delivers superior performance, service, and quality to customers.
Tackling challenges head-on: Helping enterprises build their own models
Huawei Cloud has been honing its Pangu Models by diving into industry-specific scenarios, and has worked with its customers to tackle their most pressing challenges head-on, reimagining what is possible in these industries. Huawei uses openPangu to provide best practices for AI training and inference, making it easier for developers to efficiently use AI computing power. Zhang Ping‘an noted that, at the same time, Huawei is developing the closed-source Pangu Model. Huawei will continually increase investment in Pangu Models, constantly study industry scenarios to better understand customer requirements, and support customers in developing their own industry-specific models, thus accelerating intelligent transformation across industries.
Pangu Models have been applied in more than 500 scenarios across over 30 industries. They have played a significant role in fields like government services, finance, manufacturing, healthcare, coal mining, steel, railways, autonomous driving, and meteorology.
Moving beyond terminals: Enabling infinite intelligence evolution on the cloud
This year, Huawei Cloud launched the CloudRobo Embodied AI Platform, which deploys complex algorithms and intelligent logic on the cloud to realize more lightweight robots. By taking advantage of the massive computing power and advanced AI models on the cloud, the platform makes robot execution more intelligent. Cloud intelligence overcomes the limitations that have been holding robots back, making them applicable to more scenarios.
To build a unified, open, and secure communication channel between robots and the cloud, Huawei Cloud has launched the Robot to Cloud (R2C) Protocol. Zhang Ping’an announced that the first 20 partners of the R2C Protocol were officially onboard.
Kunpeng Cloud Services: Empowering industry innovation with software-hardware synergy and an open ecosystem
One of Huawei Cloud’s key strategies is to develop Kunpeng-powered ARM cloud services that deliver performance, security, and reliability. In the past year, the number of Kunpeng compute cores on Huawei Cloud has increased from 9 million to 15 million, an increase of 67%. In addition, the Kunpeng platform has been continuously improved to support compatibility with mainstream software, and has also been adapted to more than 25,000 applications. The Kunpeng platform provides solid support for Kunpeng Cloud Services to be applied to even more general-computing scenarios, in addition to transcoding, databases, web applications, and cloud phones.
GaussDB: Building efficient, reliable data foundations based on supernodes and full pooling
Based on general-purpose computing supernodes, Huawei Cloud’s GaussDB databases realize the layered pooling of compute, memory, and storage resources, and allow multi-read and multi-write on any node at the same time, breaking free from the restrictions of the traditional architecture where only the primary node supports data read/write. GaussDB databases also support dynamic load scheduling, greatly enhancing the performance of concurrent transaction processing. A GaussDB cluster deployed based on computing supernodes can process 5.4 million transactions per minute, marking a 2.9-fold performance increase over non-supernode clusters.
All-scenario distributed cloud: Ubiquitous and best possible compute with local access
Huawei Cloud has built a distributed cloud solution covering all scenarios, including CloudOcean, CloudSea, CloudLake, and CloudPond. This covers central regions, hotspot areas, and edge sites, bringing consistent Huawei Cloud experience to wherever customers’ business is located.
Building an easy-to-use, effective, and open platform for developing and running agents
Huawei Cloud has launched Versatile, an enterprise-grade agent platform. It aims to serve as an easy-to-use, effective, and open platform for developing and running AI agents. With this platform, customers will be better equipped to quickly develop AI agents that suit their application scenarios.
Based on Versatile, users simply need to prepare and enter business description documents and flowcharts. After simple confirmation, the agent can be generated in two steps, greatly enhancing generation efficiency.
In addition to keynote speeches given at the event, Huawei Cloud brought a variety of agendas, such as summit forums and roundtables. Huawei Cloud also works with customers and partners to exhibit a wide array of innovative technologies and practices in fields such as cloud infrastructure, large models, databases, AI agents, and embodied AI, demonstrating how technology can facilitate the digital and intelligent transformation of industries.
Photo – https://mma.prnewswire.com/media/2777251/Zhang_Ping_an_Huawei_s_Executive_Director_Board_CEO_Huawei_Cloud.jpg
Continue Reading
-
EU funded Europe’s largest rare-earth magnet factory opens in Narva, Estonia
Today marks the official inauguration of Europe’s largest rare-earth magnet factory in Narva, Estonia. This EU funded factory will produce rare-earth permanent magnets to be used in key economic sectors, for example in electric vehicles, wind turbines and microelectronics. As more than 90% of magnets currently imported in the EU come from China, the new factory will greatly increase Europe’s strategic autonomy and competitiveness which are crucial for the clean and industrial transition.
Executive Vice-President for Cohesion and Reforms Raffaele Fitto said: “The inauguration of the magnet factory is a perfect example of how Cohesion Policy can make a real difference for a region and its citizens by creating new jobs and boosting the economy. But not only that: this EU funded project will also contribute to increasing the competitiveness of the whole EU. It shows once again how Cohesion policy is a win-win policy for all Europeans”.
The factory was built thanks to a support of €14.5 million from the Just Transition Fund. It will have a significant positive impact on the economy in Narva and the wider Ida-Viru County by creating up to 1,000 jobs and attracting talent from around the world. It will also greatly enhance Europe’s industrial capacity and strategic autonomy in rare-earth magnets. The factory will increase the resilience of this region and help its transition away from the extraction of oil shale, a fossil fuel-based economic activity on which the region has relied on in the past.
Continue Reading
-
Innovent Announces Mazdutide Received Approval from China’s NMPA for Glycemic Control in Adults with Type 2 Diabetes
SAN FRANCISCO and SUZHOU, China, Sept. 19, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that China’s National Medical Products Administration (NMPA) has approved mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, for glycemic control in adults with type 2 diabetes (T2D). Mazdutide is the world’s first dual GCG/GLP-1 receptor agonist approved for glycemic control in adults with T2D. It is expected to support disease management for the vast T2D population in China, achieving comprehensive benefits in glycemic control, weight reduction and hepato-cardio-renal metabolic indicators.
China has the highest number of T2D affected patients, facing urgent challenges in long-term glucose management and complication prevention
China leads the world in diabetes prevalence, with 140 million adults affected (1 in 4 global cases). Diabetes is a chronic condition where prolonged hyperglycemia can lead to severe complications, such as cardiovascular diseases, nephropathy, retinopathy and neuropathy. These complications not only endanger patients’ lives and health but also impose a significant economic burden on families and society.
In recent years, the treatment paradigm for diabetes has progressively shifted from glycemic control alone to a comprehensive, patient-centric management strategy. This approach integrates glycemic control, weight management, cardiovascular risk factor mitigation, and prevention/treatment of hepato-cardio-renal complications.
The ADA/EASD Consensus Report on the Management of Hyperglycemia in T2D has formally recognized weight reduction as a core therapeutic target. Weight loss should be prioritized not only to improve glycemic outcomes but also to reduce the risk of weight-related complications. For some patients with T2D, achieving a 5%–15% reduction in body weight is recommended as a primary treatment goal.
Mazdutide: superior glycemic control and weight loss, with hepato-cardio-renal metabolic benefits, supporting Healthy China 2030
Building upon the established effects of GLP-1 receptor agonists, dual GCG/GLP-1 receptor agonists simultaneously improve the two core pathogenic mechanisms of diabetes – insufficient insulin secretion and insulin resistance, thus, delivering comprehensive benefits beyond glycemic control, including weight loss, and hepato-cardio-renal metabolic improvements. As a safe, effective and convenient novel therapeutic option, mazdutide addresses the critical needs of long-term glucose management and complication prevention in T2D, actively supporting the realization of the “Healthy China 2030” vision.
The approval was based on two Phase 3 clinical trials (DREAMS-1 [NCT05628311] and DREAMS-2 [NCT05606913]), which evaluated the efficacy and safety of mazdutide as monotherapy and in combination with oral antidiabetic drugs, respectively, in Chinese participants with T2D. These studies demonstrated mazdutide’s superiority over placebo or dulaglutide 1.5 mg in glycemic control and weight reduction, while also showing improvements in multiple cardiometabolic, hepatic and renal parameters.
- DREAMS-1: for the efficacy estimand, at Week 24, the mean changes in HbA1c from baseline in the mazdutide 4 mg group, mazdutide 6 mg group and placebo group were -1.57%, -2.15%, and -0.14%, respectively; the proportion of participants with HbA1c <7% were 68.6%, 87.4% and 10.7%, respectively; the mean percent change in body weight from baseline were -5.61%, -7.81% and -1.26%, respectively; and the proportion of participants with HbA1c <7% and a body weight reduction≥5% were 40.6%, 64.9%, and 0%, respectively.
- DREAMS-2: for the efficacy estimand, at Week 28, the mean changes in HbA1c from baseline in the mazdutide 4 mg group, mazdutide 6 mg group and dulaglutide 1.5 mg group were -1.69%, -1.73% and -1.38%, respectively; the proportion of participants with HbA1c <7% were 71.2%, 74.2% and 62.1%, respectively; the mean percent change in body weight from baseline were -7.31%, -9.24% and -2.86%, respectively; and the proportion of participants with HbA1c <7% and a body weight reduction≥5% were 50.1%, 64.3%, and 19.4%, respectively.
Mazdutide exhibited a safety profile consistent with previous clinical studies and other GLP-1R agonists, with no new safety signals identified.
DREAMS-1 results were orally presented (Abstract #: 306-OR) at the 85th Scientific Sessions of the ADA; DREAMS-2 results were presented as a late-breaking oral presentation (Abstract #: LBA 16) at the 60th Annual Meeting of the EASD. Based on the innovative mechanism and robust evidence of mazdutide, it has been recommended in expert consensus in China..
It is worth noting that the mazdutide injection device demonstrates significant improvements in both convenience and safety compared to existing injection devices of the same type. The device features a hidden needle, ensuring the needle remains out of sight throughout the process, effectively reducing patient anxiety associated with injections. Additionally, it is a single-use device, designed for immediate disposal after use, which significantly lowers the risk of drug contamination caused by reuse or improper handling. Furthermore, the injection device incorporates innovative X-cross-section technology, delivering a smoother and painless injection experience, thereby enhancing patient comfort and treatment adherence.
Professor Dalong Zhu, the Principal Investigator of DREAMS-1 study, Nanjing University Affiliated Drum Tower Hospital, said: “China has a high prevalence of T2D globally, with over 140 million adult patients. A significant proportion of these individuals also suffer from overweight or obesity, cardiovascular diseases, and/or kidney diseases, making prevention and treatment particularly challenging. Mazdutide, as a dual GCG/GLP-1 receptor agonist, demonstrated superior efficacy in glycemic control and weight reduction compared to placebo in the DREAMS-1 study in Chinese patients with T2D inadequately managed by diet and exercise alone. It also showed a favorable safety profile. Additionally, mazdutide offered improvements such as reduced waist circumference, blood pressure and lipid levels. I am pleased to see mazdutide’s pivotal clinical study results in T2D patients have gained approval from national regulatory authorities, culminating in its market authorization, which could offer a new treatment option for T2D patients in China.”
Professor Jiajun Zhao, the Principal Investigator of DREAMS-1 study, Shandong Provincial Hospital, said: “In recent years, the treatment for diabetes has gradually shifted from mere glycemic control to a ‘patient-centered’ approach, integrating glycemic control, weight management, cardiovascular risk factor management, and addressing cardiorenal comorbidities and complications. GLP-1 receptor agonists not only excel in glycemic control but also effectively reduce weight, making them a hotspot and frontier in metabolic disease drug development. The Phase 3 study of mazdutide in participants with T2D has once again confirmed its outstanding efficacy in glycemic control and weight reduction, along with multiple metabolic benefits and a favorable safety profile. I am delighted to see the approval of mazdutide for the indication of glycemic control in adults with T2D, and I hope it will bring significant benefits to patients with T2D in China.”
Professor Lixin Guo, the principal investigator of the DREAMS-2 study, Beijing Hospital, said: “China has a high prevalence of T2D, yet the overall glycemic control rate among patients remains suboptimal. Many patients also accompany multiple cardiovascular risk factors such as obesity, hyperlipidemia, coronary heart disease, fatty liver disease, and renal diseases, which not only increase disease burden but also complicate treatment. There is an urgent clinical need for innovative therapies that demonstrate proven efficacy, favorable safety, convenient administration, and multiple cardiovascular benefits. The Phase 3 clinical study results of mazdutide in Chinese participants with T2D demonstrated not only significant glucose-lowering efficacy but also showed potential superiority over the dulaglutide in weight reduction. The approval of mazdutide for glycemic control in adults with T2D will provide more treatment options to Chinese T2D patients.”
Professor Wenying Yang, the principal investigator of the DREAMS-2 study, China–Japan Friendship Hospital, said: “In recent years, GLP-1 receptor agonists have emerged as superior therapeutic options for T2D patients by delivering comprehensive benefits in glycemic control, weight management, and cardiovascular/renal outcomes. As the first approved dual GCG/GLP-1 receptor agonist, Mazdutide demonstrated better efficacy than dulaglutide in both glucose-lowering and weight reduction during Phase 3 study in participants with T2D, while also showing multiple metabolic advantages and favorable safety profiles. These robust clinical results support its application as a next-generation GLP-1-based therapy for Chinese patients with T2D. I am delighted that Mazdutide has entered clinical practice, offering a novel treatment alternative for eligible T2D patients and contributing to improved clinical outcomes in diabetes management.”
Dr. Lei Qian, Chief R&D Officer of General Biomedicine from Innovent Biologics, stated, “Mazdutide represents the next-generation dual GCG/GLP-1 receptor agonist. Multiple clinical studies of mazdutide conducted in Chinese adults with T2D have demonstrated mazdutide’s exceptional dual advantages in both glycemic control and weight reduction across two major patient populations—those receiving monotherapy and those failing on multiple oral antidiabetic drugs. The treatment has shown multiple metabolic benefits for cardiovascular, hepatic and renal systems while maintaining an excellent safety profile. The successful approval of mazdutide reflects the national drug regulatory authority’s strong endorsement of its clinical value and safety profile, while fully validating Innovent Biologics’ innovative R&D capabilities in metabolic therapeutics. We hope mazdutide will provide superior treatment options for Chinese patients with T2D and help alleviate the disease burden on our society.”
About Diabetes
According to the 2021 global diabetes overview by the International Diabetes Federation, China leads the world in the number of patients with diabetes, with an estimated 140 million cases in 2021 and projected to reach 174 million by 2045[1]. Poor glycemic control can lead to irreversible microvascular and macrovascular complications, including reduced visual acuity, blindness, renal dysfunction, peripheral neuropathy, myocardial infarction, stroke and amputation[2]. The high prevalence of diabetes and its serious complications pose a significant threat to human health. Currently, various therapeutic approaches are available for diabetes management. In addition to controlling blood glucose, new hypoglycemic drugs are being developed to offer additional benefits such as weight loss, cardiovascular risk reduction and kidney protection[3].
About Mazdutide
Innovent entered into an exclusive license agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of mazdutide, a dual GCG /GLP-1 receptor agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, in addition to the effects of GLP-1 receptor agonists on promoting insulin secretion, lowering blood glucose and reducing body weight, mazdutide may also increase energy expenditure and improve hepatic fat metabolism through the activation of glucagon receptor. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies, as well as reducing waist circumference, blood lipids, blood pressure, serum uric acid, liver enzymes, liver fat content and improved insulin sensitivity.
Mazdutide has conducted seven Phase 3 clinical studies, including:
- GLORY-1: A Phase 3 clinical study conducted in Chinese adults with overweight of obesity;
- GLORY-2: A Phase 3 clinical study conducted in Chinese adults with moderately to severely obesity;
- GLORY-3: A Phase 3 clinical study comparing mazdutide versus semaglutide in Chinese adults with overweight of obesity accompanied metabolic-associated fatty liver disease (MAFLD);
- GLORY-OSA: A Phase 3 trial in Chinese participants with obstructive sleep apnea (OSA) and obesity;
- DREAMS-1: A Phase 3 clinical study conducted in Chinese adults with untreated type 2 diabetes;
- DREAMS-2: A Phase 3 clinical study comparing mazdutide versus dulaglutide in Chinese adults with type 2 diabetes who have poor glycemia control with oral medication;
- DREAMS-3: A Phase 3 clinical study comparing mazdutide versus semaglutide in Chinese adults with type 2 diabetes and obesity;
Among these, GLORY-1, DREAMS-1, and DREAMS-2 have already met their primary endpoints and the other four studies are currently ongoing.
In addition, several new clinical studies of mazdutide are initiated or planned, including:
- A Phase 3 trial in adolescents with obesity;
- New studies in patients with metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF).
*Mazdutide has received NMPA approval for two indications:
First Indication: as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial Body Mass Index (BMI) of:
- BMI ≥ 28 kg/m² (obesity); or
- BMI ≥ 24 kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hyperglycemia, hypertension, dyslipidemia, fatty liver, or obstructive sleep apnea syndrome and etc.);
Second Indication (Newly Approved): glycemic control in adults with type 2 diabetes:
Monotherapy
For adults with type 2 diabetes who have inadequate glycemic control despite diet and exercise interventions.
Combination Therapy
For adults with T2D who still have poor glycemic control despite:
Diet and exercise, plus Metformin and/or sulfonylureas, or Metformin and/or SGLT2 inhibitors (SGLT2i).
About Innovent Biologics
Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 16 products in the market. It has 2 new drug applications under regulatory review, 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.
Guided by the motto, “Start with Integrity, Succeed through Action” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.
Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s).
Forward-looking statement
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.
Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.
References
[1]. Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projects for 2045 [published correction appeals in Diabetes Res Clin Pract. 2023 Oct; 204: 110945]. Diabetes Res Clin Pract. 2022; 183: 109119. doi: 10.1016/j.diabres.2021. 109119
[2]. Gregg EW, Sattar N, Ali MK. The changing face of diabetes complications. Lancet Diabetes Endocrinol. Published online 2016. doi: 10.1016/S2213-8587 (16) 30010-9
[3]. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art. Mol Metab. Published online 2020. doi: 10.1016/j.molmet.2020. 101102
SOURCE Innovent Biologics
Continue Reading
-
Engine Work Management System for Industrial Switchgears
Siemens presents an innovative motor management system for industrial switchgear
- Optimized space utilization and innovative Single Pair Ethernet (SPE) communication physics for withdrawable cabinet design
- Scalable functionality enabled by licensed device features
- Reduced installation costs
Siemens has launched SIMOCODE M-CP, an efficient and future-oriented product series for motor operation management, specifically tailored for Motor Control Centers (MCC). The new product line complements the existing SIMOCODE portfolio and has been designed to optimally meet MCC requirements. SIMOCODE M-CP sets a new industry standard with its compact design, advanced functionality, and compatibility with Ethernet-based communication.
In the future, SIMOCODE M-CP can be adapted to various operational needs through the purchase of licenses that unlock additional functionalities depending on the application.
Motor Control Centers are designed to efficiently distribute power to motors, enable precise control and monitoring, and provide protection against overloads, short circuits, and other electrical faults. These solutions are used in industries such as chemical, paper, steel, mining, water and wastewater, and infrastructure.
SIMOCODE M-CP
Space-saving and flexible installationThe new SIMOCODE M-CP is optimized for withdrawable modules in low-voltage switchgear. With the option to choose between front panel mounting and DIN rail mounting, this versatile device allows for efficient space utilization and reduced installation costs. More integrated functions in the base unit reduce the need for variety. Six digital inputs and four relay outputs eliminate the need for additional modules.
Advanced communication with Single Pair Ethernet technologyTo enable fast and reliable data transmission, SIMOCODE M-CP uses Single Pair Ethernet (SPE) technology. This new bus physics ensures uninterrupted Ethernet communication and meets the operational needs of switchgear while reducing wiring complexity. Communication with the withdrawable module is carried out via just two wires.
Future-proof technology with reloadable and licensable functionsIn the future, SIMOCODE M-CP can be adapted to various operational requirements through the purchase of licenses that enable additional functionalities depending on the application. This reduces the need to purchase and install separate components and makes the system future-proof. One example is the integration of condition monitoring directly into the motor management system itself. This eliminates the need for separate sensors. Key drive operating parameters can now be monitored using current and voltage measurement modules, simplifying configuration. By purchasing a license, users can activate data delivery via SIMOCODE M-CP to enable advanced motor current signature analysis (MCSA) or use artificial intelligence to detect anomalies and faults in machines, streamlining processes and increasing reliability.
SIMOCODE M-CP in a withdrawable module
Built-in sustainabilityIn addition to using recycled materials for production and packaging, the high product quality results in long service life. Thanks to numerous diagnostic functions, SIMOCODE M-CP can help increase system availability and extend motor lifespan by providing early warnings in case of irregularities. Long-term firmware updates also help ensure that SIMOCODE M-CP remains functional and up-to-date for many years.
Additional informationSIMOCODESiemens Energy
Continue Reading
-
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 September 2025
14 new medicines recommended for approval
EMA’s human medicines committee (CHMP) recommended 14 medicines for approval at its September 2025 meeting.
The committee recommended granting a marketing authorisation for Enflonsia (clesrovimab), a medicine indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. RSV is a common respiratory virus that usually causes symptoms similar to the common cold but can also affect the lungs. Almost all children get an RSV infection by the time they are two years old. While most recover quickly, in some children RSV can cause severe illness that may lead to hospitalisation and even death.
The CHMP recommended granting a marketing authorisation for Imaavy (nipocalimab), for the treatment of generalised myasthenia gravis, a disease that leads to muscle weakness and tiredness.
A positive opinion was adopted for Kyinsu (insulin icodec / semaglutide), for the treatment of adults with type 2 diabetes insufficiently controlled on basal insulin or glucagon-like peptide 1 (GLP-1) receptor agonists. Kyinsu is used together with diet, exercise and oral medicines to treat diabetes.
Lynkuet (elinzanetant) received a positive opinion from the CHMP for the treatment of moderate-to-severe vasomotor symptoms, also referred to as hot flushes or night sweats, associated with menopause.
The committee adopted positive opinions for nine biosimilar medicines:
- Acvybra (denosumab), Denosumab Intas (denosumab), Kefdensis (denosumab), and Ponlimsi (denosumab), for the treatment of osteoporosis and bone loss.
- Degevma (denosumab), Xbonzy (denosumab), and Zvogra (denosumab), for the prevention of skeletal-related events in adults and treatment of adults and skeletally-mature adolescents with giant cell tumour of bone.
- Gobivaz (golimumab), for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis and ulcerative colitis.
- Usgena (ustekinumab), for the treatment of Crohn’s disease, plaque psoriasis and paediatric plaque psoriasis, psoriatic arthritis, and ulcerative colitis.
A generic medicine, Rivaroxaban Koanaa (rivaroxaban), received a positive opinion for the prevention of venous thromboembolism, the treatment and prevention of deep vein thrombosis and pulmonary embolism, and the prevention of stroke and systemic embolism in adults with various risk factors for such events, as well as the treatment and prevention of venous thromboembolism in children and adolescents.
Recommendations on extensions of therapeutic indication for six medicines
The committee recommended extending the therapeutic indication of Uplizna (inebilizumab), a medicine used to treat adults with neuromyelitis optica spectrum disorders, to include the treatment of active immunoglobulin G4-related disease, a rare autoimmune disease for which currently there are no authorised medicines in the EU. See more details in the news announcement in the grid below.
The committee recommended another five extensions of indication for medicines that are already authorised in the EU: Bimervax, Dupixent, Keytruda, Koselugo, and Tezspire.
For Keytruda, the committee also recommended a new pharmaceutical form and a new strength for subcutaneous administration.
Withdrawal of applications
Applications for initial marketing authorisation for four medicines were withdrawn:
- Amtagvi (lifileucel), a medicine to treat melanoma that is unresectable (cannot be removed by surgery) or metastatic (has spread to other parts of the body) in adults.
- Fanskya (mozafancogene autotemcel), for the treatment of paediatric patients with Fanconi Anaemia Type A.
- Tuzodi (midazolam), for the treatment of prolonged, acute, convulsive seizures in adults, adolescents, children and toddlers from two years of age.
- Omforro (midazolam), for the conscious sedation before and during diagnostic or therapeutic procedures with or without local anaesthesia and premedication before induction of anaesthesia.
Question-and-answer documents on the withdrawals of these medicines are available in the grid below.
Outcome of re-examination
Following a re-examination, the committee recommended granting a marketing authorisation for Winlevi (clascoterone), a medicine intended for the topical treatment of acne vulgaris in adults and adolescents. The positive opinion was adopted in August 2025.
After a re-examination of its initial opinion at the request of the applicant, the CHMP confirmed its initial recommendation to refuse the marketing authorisation for Atropine sulfate FGK (atropine sulfate), a medicine intended for the treatment of myopia (short-sightedness) in children aged 6 to 10 years.
For more information, see the question-and-answer documents in the grid below.
Other updates
The CHMP gave a positive opinion to update the composition of the vaccine Bimervax to target the new SARS-CoV-2 LP.8.1 variant of the virus that causes COVID-19. The revision of this vaccine is in line with the recommendation issued by EMA’s Emergency Task Force to update COVID-19 vaccines to target the SARS-CoV-2 variant LP.8.1 for the 2025/2026 vaccination campaign.
The committee adopted a new route of administration for Lunsumio, a cancer medicine used to treat adults with follicular lymphoma that does not respond to (refractory) or has come back (relapsed) after at least two previous treatments.
The CHMP finalised its assessment of an application to extend the use of Lutathera* (lutetium (177Lu) oxodotreotide), a cancer medicine for treating tumours in the gut, to adolescents aged 12 years and older with unresectable or metastatic, somatostatin receptor-positive gastro-entero-pancreatic neuroendocrine tumours. Although EMA did not recommend this use, it agreed that relevant data from the study submitted with the application be included in the medicine’s product information so that healthcare professionals have access to up-to-date information. A question-and-answer document on the update is available in the grid below.
The CHMP also adopted a change to the existing indication and contraindications of Norvir (ritonavir), a medicine to treat patients who are infected with human immunodeficiency virus type 1 (HIV 1), a virus that causes acquired immune deficiency syndrome (AIDS).
Agenda and minutes
The agenda of the September 2025 CHMP meeting is published on EMA’s website. Minutes of the meeting will be published in the coming weeks.
CHMP statistics
Key figures from the September 2025 CHMP meeting are represented in the graphic below.
*This product was designated as an orphan medicine during its development. Orphan designations are reviewed by EMA’s Committee for Orphan Medicinal Products (COMP) at the time of approval to determine whether the information available to date allows maintaining the medicine’s orphan status and granting the medicine ten years of market exclusivity.
Continue Reading
-
First treatment recommended for rare immunoglobulin-related autoimmune disease
EMA’s human medicines committee (CHMP) has recommended extending the therapeutic indication of Uplizna (inebilizumab) to include the treatment of adult patients with active immunoglobulin G4-related disease (IgG4-RD).
IgG4-RD is a rare, chronic, autoimmune condition (a disease caused by the body’s own defence system attacking normal tissue) that can cause fibrosis (tissue scarring) and inflammations in one or multiple organs. Patients with IgG4-RD suffer from new or worsening signs and symptoms in one or more organs. The consequences of inflammation manifest gradually or acutely and can lead to irreversible organ damage and dysfunction. IgG4-RD normally affects people between the ages of 40 and 60.
There are currently no authorised medicines in the EU for the treatment of adults with IgG4-RD, and patients are commonly treated with glucocorticoids and other immunomodulatory medicines. Some patients show significant reductions in the size of lesions and improvement in laboratory test results, but others fail to achieve complete remission or relapse within one year. In addition, side effects associated with the use of glucocorticoids, including high blood pressure, high blood sugar, osteoporosis (thinning bones), a weakened immune system and muscle weakness, are more likely to occur in older patients. There is therefore a high unmet medical need for steroid-sparing treatments in patients with IgG4-RD.
Uplizna contains inebilizumab, a monoclonal antibody (a type of protein) that attaches to immune cells called B cells and destroys them. Uplizna is already approved to treat patients with neuromyelitis optica spectrum disorders (NMOSD).
The CHMP based its recommendation on the assessment of efficacy and safety data from a phase 3, randomised, double blind, 52-week clinical trial in 135 adult patients with active IgG4-RD who received either intravenous Uplizna or matching placebo on day 1, day 15, and week 26. The median time to the first treated IgG4-RD flare was significantly longer in patients receiving Uplizna. Similarly, of the 68 patients receiving Uplizna, only seven were treated for IgG4 RD flares, compared to 40 of the 67 patients receiving placebo. In addition, 58.8% of patients receiving Uplizna achieved corticosteroid-free, flare-free complete remission (a period without disease symptoms after treatment) at week 52, compared to 22.4% of patients receiving placebo.
The safety profile of Uplizna in patients with IgG4 RD or in patients with NMOSD was generally consistent. The most common side effects were infections (including urinary tract infections, nasopharyngitis and upper respiratory tract infections), joint pain, back pain and low levels of lymphocytes, a type of white blood cell.
The opinion adopted by the CHMP is an intermediary step on Uplizna’s path to patient access. The opinion will now be sent to the European Commission for the adoption of a decision on an EU-wide extension of the therapeutic indication. Once an extension has been granted, decisions about price and reimbursement will take place at the level of each Member State, taking into account the potential role or use of these medicines in the context of the national health system of that country.
- The marketing authorisation holder for Uplizna is Amgen Europe B.V.
Continue Reading